Glycerol 3-phosphate |
Catalog No.GC36159
One-Click Copy Product Info
|
Glycerol 3-phosphate is produced by the cytosolic glycerol 3-phosphate dehydrogenase pathway. Cytosolic glycerol 3-phosphate dehydrogenase (GPDH) consumes NADH to produce glycolol 3-phosphate from dihydroxyacetone phosphate (DHAP). The generated glycolol 3-phosphate can cross the permeable outer mitochondrial membrane. Glycerol 3-phosphate is unstable in its free form, and its stable salt form sn-Glycerol 3-phosphate lithium (GC61482) with the same biological activity is recommended.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 17989-41-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Glycerol 3-phosphate is produced by the cytosolic glycerol 3-phosphate dehydrogenase pathway. Cytosolic glycerol 3-phosphate dehydrogenase (GPDH) consumes NADH to produce glycolol 3-phosphate from dihydroxyacetone phosphate (DHAP). The generated glycolol 3-phosphate can cross the permeable outer mitochondrial membrane[1]. Glycerol 3-phosphate is unstable in its free form, and its stable salt form sn-Glycerol 3-phosphate lithium (GC61482) with the same biological activity is recommended.
Glycerol 3-phosphate alone can inhibit the proliferation of DU145 and A549 cells in a concentration-dependent manner, and Glycerol 3-phosphate can increase the sensitivity of cells to metformin. When the concentration of Glycerol 3-phosphate is equal to or less than 1mmol/L, it has no adverse effect on the oxygen consumption rate (OCR) of DU145 and A549 cells, but as the concentration of Glycerol 3-phosphate increases (10, 100mmol/L), OCR begins to be inhibited[2].
In C57Bl/6J mice, plasma intact fibroblast growth factor 23 (iFGF23) and C-terminal FGF23 (cFGF23) levels showed a dose-dependent increase after a single intraperitoneal injection of Glycerol 3-phosphate (50, 150 and 300mg/kg). Glycerol 3-phosphate increased the urine phosphate/creatinine ratio and decreased plasma 1,25-dihydroxyvitamin D3 levels[3]. In a myocardial ischemia-reperfusion (I/R) mouse model, glycerol 3-phosphate reduced myocardial infarction area (42 ± 2%) compared with the control group (56 ± 4%) by activating the quinone pool (Q-pool) to stimulate the production of ROS in complex III (antimycin A)[4].
References:
[1] Shen W, Wei Y, Dauk M, et al. Involvement of a glycerol-3-phosphate dehydrogenase in modulating the NADH/NAD+ ratio provides evidence of a mitochondrial glycerol-3-phosphate shuttle in Arabidopsis[J]. The Plant Cell, 2006, 18(2): 422-441.
[2] Xie J, Ye J, Cai Z, et al. GPD1 enhances the anticancer effects of metformin by synergistically increasing total cellular glycerol-3-phosphate[J]. Cancer research, 2020, 80(11): 2150-2162.
[3] Simic P, Kim W, Zhou W, et al. Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney[J]. The Journal of clinical investigation, 2020, 130(3): 1513-1526.
[4] Madungwe N B, Zilberstein N F, Feng Y, et al. Critical role of mitochondrial ROS is dependent on their site of production on the electron transport chain in ischemic heart[J]. American journal of cardiovascular disease, 2016, 6(3): 93.
| Cell experiment [1]: | |
Cell lines | DU145 and A549 cells |
Preparation Method | DU145 and A549 cells were treated with different concentrations of Glycerol 3-phosphate and 2.5mmol/L metformin, and cell viability was detected by CCK-8 method. |
Reaction Conditions | 1-200mmol/L |
Applications | Glycerol 3-phosphate alone inhibited the proliferation of DU145 and A549 cells, and Glycerol 3-phosphate significantly improved the anti-proliferation ability of metformin. |
| Animal experiment [2]: | |
Animal models | C57Bl/6J mice |
Preparation Method | Glycerol 3-phosphate, LPA, sodium phosphate dibasic, G-2-P, glycerol , 1,25(OH)2D , and IL-6 were i.p. injected into 3–10 mice per group. Mice were sacrificed 24h after i.p. injection, and blood, femur, bone marrow, and other tissues were collected for further analysis. |
Dosage form | 50, 150 and 300mg/kg, 24h, i.p. |
Applications | In C57Bl/6J mice, plasma iFGF23 and C-terminal FGF23 (cFGF23) levels demonstrated a dose-dependent increase following a single dose of Glycerol 3-phosphate, with no change in the cFGF23/iFGF23 ratio. |
References: [1] Xie J, Ye J, Cai Z, et al. GPD1 enhances the anticancer effects of metformin by synergistically increasing total cellular glycerol-3-phosphate[J]. Cancer research, 2020, 80(11): 2150-2162. [2] Simic P, Kim W, Zhou W, et al. Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney[J]. The Journal of clinical investigation, 2020, 130(3): 1513-1526. | |
| Cas No. | 17989-41-2 | SDF | |
| Canonical SMILES | O[C@H](CO)COP(O)(O)=O | ||
| Formula | C3H9O6P | M.Wt | 172.07 |
| Solubility | Water: ≥ 50 mg/mL (290.58 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 5.8116 mL | 29.0579 mL | 58.1159 mL |
| 5 mM | 1.1623 mL | 5.8116 mL | 11.6232 mL |
| 10 mM | 581.2 μL | 2.9058 mL | 5.8116 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)